T1	Participants 602 695	50 patients (serum creatinine, 1.5-3.9 mg/dL) with high-normal body lead burden (≥80-<600 μg)
T2	Participants 1946 2014	17 (68%) control-group patients and 9 (36%) treatment-group patients
